BTK Inhibitors: An Emerging Target in Multiple Sclerosis
Released On
December 14, 2022
Expires On
December 14, 2023
Media Type
Internet
Completion Time
45 minutes
Specialty
Neurology, Primary Care
Topic(s)
Multiple Sclerosis
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Integrity Continuing Education, Inc.
This activity is supported by an educational grant from Sanofi.
Credit Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of neurologists, primary care physicians, nurse practitioners, physician assistants, and other advanced health care professionals who manage patients with MS.
Program Overview
Multiple sclerosis (MS) is a chronic inflammatory condition that affects approximately 1 million US adults. The disease is marked by central nervous system (CNS) demyelination that results in fatigue, spasticity, and pain, among many other symptoms that negatively impact quality of life. Appreciation for the need to prevent increasing CNS damage and disability accumulation in patients with MS continues to drive efforts to identify new disease-modifying therapies with the potential for greater efficacy and long-term safety. Among the new candidates are multiple Bruton's tyrosine kinase (BTK) inhibitors, which exert their therapeutic effects by targeting B-cell receptor signaling.
Join our esteemed clinician faculty for a review of the clinical rationale for BTK inhibition in MS treatment, and the efficacy and safety of BTK inhibitor therapies currently in late-stage development. The program will conclude with an interactive mechanism of action activity and access to a downloadable resource.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Improve knowledge of clinicians on the role of BTK inhibition in MS management
- Describe the mechanisms of action for emerging BTK inhibitors
- Recall available safety and efficacy data for emerging BTK inhibitors
Click for the BTK Inhibitors - An Emerging Target in Multiple Sclerosis_downloadable slides
Faculty
Daniel S. Reich, MD, PhD
Chief, Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), USA. He appears here in his private capacity, as an approved Outside Activity, and the views and opinions here do not represent those of NINDS or NIH.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
- Daniel S. Reich, MD, PhD
-
- Collaborative Research: Abata Therapeutics, Sanofi
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of December 14, 2022 through December 14, 2023, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.